Jan. 30 at 3:50 PM
$IFRX CMC and manufacturing readiness
Confirm the status of manufacturing transfer/CMC documentation, any outstanding stability or comparability studies, and the earliest date that a complete CMC module can be submitted.
Milestones, dependencies and realistic timeline
Provide a short milestone schedule (dates or quarters) for the next 9–18 months, including: completion of outstanding studies, dossier submission, expected NMPA review window, and commercial launch assumptions.
Commercial and contractual constraints affecting timing
Clarify any contractual, exclusivity or regulatory conditions in the InflaRx–Staidson agreement that could accelerate or delay filing or approval (e.g., data sharing limits, milestone triggers, or local clinical requirements).
Please attach or indicate availability of a one‑page roadmap or Gantt showing the above milestones if possible.
